samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Nemera reinforces its value proposition with a refreshing visual identity

Nemera

More modern, our new brand identity truly embodies who we are, how we partner with our customers and ultimately the value we bring to millions of patients across the world through our drug delivery device solutions.


At Nemera, we have been successfully providing high quality drug delivery device solutions to our customers and patients for years. We design and manufacture devices with the ultimate goal to improve patient outcomes and experience. We are passionately growing our business around the combination product value chain through our holistic offering. We partner with our customers in an agile manner to accelerate bringing their products to patients. As our business evolves, we are pleased to introduce our new visual identity that reflects this transformation.

“We are thrilled to launch our new identity that re-unites our purpose of putting patients first and our commitment of being a holistic and agile partner. Together, they tell the unique story of our heritage and where we are headed alongside our customers in the drug delivery devices industry.” says Marc Hämel, Nemera’s CEO

Different look. Same commitment.

Our website. A user-friendly, easy to navigate and content rich website that not only tells our story but also helps understand how we support our customers with our products, services and capabilities. It also makes it easier to contact and work with us. Live the experience at www.nemera.net and our social media channels! Our logo. Warm, friendly and forward looking, our logo speaks to our open, inclusive and patient-centric ethos.


phone +33 4 74 94 06 54
email information@nemera.net
web www.nemera.net
email 20 avenue de la Gare, 38290 – La Verpillière, France
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Juvisé Pharmaceuticals Successfully Complete a €400M Refinancing Following the Acquisition of the Worldwide Rights of Pylera

Paris, France, July 5, 2022: The French speciality pharmaceutical company, Juvisé Pharmaceuticals has recently completed a transaction with AbbVie, regarding the acquisition of the worldwide commercial rights of Pylera®. Details of this transaction remain undisclosed.
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

Connect in Pharma

14-15 September 2022, Plaexpo, Geneva, Switzerland

The new event driving innovation for pharma and biopharma businesses, Connect in Pharma will unite key players in Pharmaceutical and Biopharmaceutical packaging and production in Geneva on 14 – 15 September 2022.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement